Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATAI
ATAI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATAI News
AtaiBeckley Inc. Gains Bullish Support from H.C. Wainwright
3d ago
Yahoo Finance
Wall Street's Latest Ratings Overview
3d ago
CNBC
ATAIBECKLEY INC: DEUTSCHE BANK STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $12
3d ago
moomoo
AtaiBeckley Reports Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression
Mar 17 2026
seekingalpha
Atai Beckley Analysts Maintain Buy Ratings with $14 Price Target
Mar 10 2026
Benzinga
AtaiBeckley Advances BPL-003 Treatment Plan
Mar 10 2026
Newsfilter
Helus Pharma Advances New Drug for Anxiety Treatment
Mar 09 2026
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
Mar 09 2026
PRnewswire
AtaiBeckley Explores Strategic Options for BPL-003
Mar 07 2026
seekingalpha
Atai Beckley Reports Q4 Loss with $1.06M Revenue
Mar 06 2026
seekingalpha
AtaiBeckley Reports Q4 and Full Year 2025 Financial Results
Mar 06 2026
NASDAQ.COM
Helus Pharma's HLP004 Phase 2 Study Results Disappoint
Mar 05 2026
Benzinga
Helus Pharma Advances Mental Health Drug Development
Feb 27 2026
Newsfilter
Helus Pharma Advances Psychedelic Drug Clinical Trials
Feb 27 2026
PRnewswire
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
AtaiBeckley Reports Positive EMP-01 Trial Results for Social Anxiety Disorder
Feb 26 2026
Benzinga
Show More News
